Nephron Pharmaceuticals
Nephron Pharmaceuticals is a privately-held, woman-owned U.S. manufacturer of generic respiratory medications and a registered 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags for hospitals, using Blow-Fill-Seal technology from its West Columbia, South Carolina facilities.
- Company typePrivate
- Founded1997
- HeadquartersFlorida, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nephron Pharmaceuticals does
Nephron Pharmaceuticals Corporation is a privately-held, woman-owned U.S. pharmaceutical manufacturer founded in 1997 and headquartered in West Columbia, South Carolina. The company operates across three primary lines: (1) generic inhalation solutions and suspension products (Albuterol, Budesonide, Ipratropium Bromide, Sodium Chloride, and the OTC Asthmanefrin brand) for asthma, emphysema, and COPD patients; (2) a registered 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags to address FDA-listed drug shortages in hospitals and surgery centers; and (3) contract manufacturing services for outside pharmaceutical partners. Distribution runs through direct hospital sales, retail and mail-order pharmacies, home care companies, and long-term care facilities, with EDI integration via GHX and supply-chain serialization via Kit Check RFID.
The company's technical backbone is Blow-Fill-Seal (BFS) manufacturing, a continuous form-fill-seal process that produces vials in a closed, sterile environment without human intervention, supplemented by Growth Direct automated microbial monitoring, robotic syringe-filling automation co-developed with the University of South Carolina and Clemson University, laser-guided unmanned forklifts, and RFID-based supply-chain tracking. Nephron's 840,000+ square-foot LEED Silver-certified West Columbia facility produces over one billion doses annually, and the company operates a separate 400,000 square-foot nitrile glove plant (Nephron Nitrile) established in 2021.
Nephron generates revenue primarily through unit sales of generic respiratory medications (priced 80-85% below brand equivalents) and transactional 503B sterile compounding for hospital customers, with contract manufacturing as a third revenue stream. Pricing is mediated through a dedicated B2B sales team rather than public price lists, and customers order through a company portal or GHX EDI. The company is led by co-owners Lou Kennedy (President and CEO since 2007) and Bill Kennedy, with CEO Lou Kennedy also chairing the South Carolina Chamber of Commerce. Nephron has raised approximately $700 million in institutional capital since 2023 from BlackRock, PNC Bank, and WhiteHawk Capital Partners to fund ongoing expansion.
Nephron Pharmaceuticals firmographics
Firmographics- Name
- Nephron Pharmaceuticals
- Legal name
- Nephron Pharmaceuticals Corporation
- Website
- https://nephronpharm.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Nephron Pharmaceuticals is a privately-held, woman-owned U.S. manufacturer of generic respiratory medications and a registered 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags for hospitals, using Blow-Fill-Seal technology from its West Columbia, South Carolina facilities.
- Ownership category
- akta.pro rank
Nephron Pharmaceuticals industry classification
Industry- Product category
- Generic Respiratory Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Nephron Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Florida
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nephron Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Generic Inhalation Medications: Development and manufacturing of generic respiratory medications including inhalation solutions and suspension products for patients with asthma, emphysema, and COPD
- 503B Outsourcing Services: Sterile compounding services producing pre-filled syringes and IV bags for hospitals to address drug shortages; operates as cGMP manufacturer
- Contract Manufacturing: Manufacturing high-quality, sterile medications for hospitals and medical facilities; over 27 years of experience in contract manufacturing
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Generic respiratory medications at 80-85% lower cost than brand equivalents |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Nephron Pharmaceuticals product offering
Product offeringCore offering
Nephron Pharmaceuticals develops and manufactures generic respiratory inhalation solutions and suspension products (including Albuterol, Budesonide, Ipratropium Bromide, Sodium Chloride, and Racepinephrine) for patients with asthma, emphysema, and COPD. The company also operates a cGMP 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags for U.S. hospitals to address persistent drug shortages, and provides contract pharmaceutical manufacturing services leveraging Blow-Fill-Seal technology.
Product overview
Nephron Pharmaceuticals is a manufacturer of generic respiratory medications and sterile pharmaceutical products. The company operates three main divisions: (1) Generic Inhalation Solutions and Suspension Products including Albuterol, Budesonide, Ipratropium Bromide, Racepinephrine, and Sodium Chloride solutions; (2) A 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags for hospitals; and (3) Contract Manufacturing services using blow-fill-seal (BFS) technology. Additional offerings include Nephron Nitrile for medical-grade gloves and the Pocket Neb portable nebulizer through partnership with Micro Vapor Devices. The company produces over one billion doses annually from its 840,000+ square foot LEED-certified facilities in West Columbia, South Carolina.
Differentiator
Problem solved
Functional benefit
Brands
- Nephron Nitrile: A subsidiary company producing American-made, medical-grade nitrile gloves for PPE supply chain.
Products and services
- Generic Inhalation Solutions and Suspension Products Safe, affordable generic inhalation solutions and suspension products including Albuterol (0.021%, 0.042%, 0.083%, 0.5%), Budesonide (0.25 mg/2 mL and 0.5 mg/2 mL), Ipratropium Bromide 0.02%, Ipratropium/Albuterol combinations, hypertonic Sodium Chloride (3% and 7%), and Racepinephrine (Asthmanefrin) for patients with asthma, emphysema, COPD, and other respiratory ailments.
- 503B Outsourcing Facility (Sterile Pre-Filled Syringes and IV Bags) cGMP 503B Outsourcing Facility producing sterile pre-filled syringes (including controlled substances and cardiac medications) and IV bags for U.S. hospitals and surgery centers to address persistent FDA-listed drug shortages.
- Contract Pharmaceutical Manufacturing Contract manufacturing services with 27+ years of experience producing high-quality, sterile medications for hospitals and medical facilities across America using Blow-Fill-Seal (BFS) technology.
- Pocket Neb Portable Nebulizer Lightweight, portable vibrating mesh nebulizer developed in partnership with Micro Vapor Devices for prescription-only delivery of respiratory medications.
- Nephron Nitrile Medical-Grade Gloves Medical-grade nitrile gloves manufactured in the United States by Nephron Nitrile (a wholly-owned subsidiary) using molds from CeramTec, addressing PPE supply chain needs with a 400,000 sq ft facility at Saxe-Gotha Industrial Park.
Quantifiable outcome
- 80-85% lower cost than brand name products
- +3 more outcomes
Companies that use Nephron Pharmaceuticals
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Nephron Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Nephron Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- CeramTeccorePartnership with global ceramic and medical technology company to produce nitrile gloves. CeramTec provides forms used in molding the gloves at Nephron Nitrile facility.
- Dominion Energy South CarolinaminorPartnership to launch drive-thru COVID-19 vaccination site. Dominion provided space, power and logistics support for community vaccination efforts.
- University of South CarolinacorePartnership with USC colleges of engineering and pharmacy to develop robotic syringe-filling system. Includes Kennedy Pharmacy Innovation Center establishment and ongoing collaboration on automation.
- InfuTronix SolutionsminorPartnership to offer cost-effective, efficient non-narcotic therapy solution for post-operative pain management.
- Clemson UniversitycorePartnership to create robotic solution for syringe-filling automation to enhance sterile manufacturing. Engages College of Engineering faculty and students in robotics research for automation.
- Rapid Micro BiosystemscoreImplemented Growth Direct automated microbial monitoring system - first and only growth-based system of its kind in microbial testing, enabling 50% faster detection.
- Global Healthcare Exchange (GHX)coreElectronic Data Interchange (EDI) ordering through GHX cloud-based platform, enabling customers to purchase products on FDA drug shortage list in one step.
- Kit CheckcoreImplementation of RFID tags on all prefilled syringe products for supply chain serialization and tracking. Nephron is first company implementing Kit Check across all syringe products.
- UPSminorEnhanced partnership for complimentary overnight shipping via UPS Next Day Air Saver service for all drug shortage product orders.
- Apotex, Inc.coreLicensed Abbreviated New Drug Application for Budesonide Inhalation Suspension from Apotex. Nephron handles manufacturing, marketing and distribution.
Scale indicators9 records
Recent moves11 records
Expansion highlights6 records
Nephron Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Hospira (Pfizer CenterOne): Pfizer's contract and injectables manufacturing arm is a direct competitor in sterile injectable manufacturing and 503B outsourcing, serving the same hospital pharmacy customers with pre-filled syringes and IV bags.
- Viatris (formerly Mylan): Major generic respiratory pharmaceutical manufacturer producing generic albuterol, ipratropium, and budesonide inhalation products - directly competitive in Nephron's core therapeutic area and distribution channels.
- Amneal Pharmaceuticals: U.S. generic pharmaceutical manufacturer with focus on inhalation, injectables, and specialty products; directly competes with Nephron in generic respiratory and hospital injectable segments.
- Lannett Company: U.S. generic pharmaceutical manufacturer with a portfolio that includes respiratory generics and sterile injectable products, serving similar hospital and retail pharmacy customers as Nephron.
- Akorn Operating Company: Specialty generic pharmaceutical manufacturer producing respiratory, sterile injectable, and topical products; competes directly in hospital and specialty pharmacy channels.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with significant respiratory franchise including branded and generic inhalation products; competes broadly with Nephron across hospital and retail channels.
- Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars with respiratory and sterile injectable portfolios; competes in generic inhalation solutions and contract manufacturing markets.
- Catalent (Novo Holdings): Major contract development and manufacturing organization (CDMO) with sterile injectable and inhalation capabilities; competes with Nephron's contract manufacturing division and 503B outsourcing services.
Emerging players
- Becton, Dickinson and Company (BD): Large medical device and drug delivery company with pre-filled syringe and injection systems; relevant comparable for Nephron's 503B pre-filled syringe business and broader drug delivery strategy.
Others
- Adamis Pharmaceuticals: Specialty pharmaceutical company with US Compounding subsidiary - was adverse party in Nephron's $7.9M trade secrets settlement; operates in adjacent 503B and compounding space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Nephron Pharmaceuticals social profiles
Digital presenceNephron Pharmaceuticals compliance and trust
Trust signalCompliance5 records
Nephron Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nephron Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles17 records
Nephron Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Nephron Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nephron Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nephron Pharmaceuticals
What does Nephron Pharmaceuticals do?
Nephron Pharmaceuticals develops and manufactures generic respiratory inhalation solutions and suspension products (including Albuterol, Budesonide, Ipratropium Bromide, Sodium Chloride, and Racepinephrine) for patients with asthma, emphysema, and COPD. The company also operates a cGMP 503B Outsourcing Facility producing sterile pre-filled syringes and IV bags for U.S. hospitals to address persistent drug shortages, and provides contract pharmaceutical manufacturing services leveraging Blow-Fill-Seal technology.
Is Nephron Pharmaceuticals a public or private company?
Nephron Pharmaceuticals is a private company. It is classified as family owned and is currently operating.
When was Nephron Pharmaceuticals founded?
Nephron Pharmaceuticals was founded in 1997. It employs 501 to 1,000 people.
Where is Nephron Pharmaceuticals based?
Nephron Pharmaceuticals is headquartered in Florida, United States, in the North America region.
How does Nephron Pharmaceuticals make money?
Three revenue lines are on record. Generic Inhalation Medications are the primary driver. The others are 503B Outsourcing Services and contract Manufacturing.
Who are Nephron Pharmaceuticals's main competitors?
Direct peers on record are Hospira (Pfizer CenterOne), Viatris (formerly Mylan), Amneal Pharmaceuticals, Lannett Company and Akorn Operating Company. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis) and Catalent (Novo Holdings). Becton, Dickinson and Company (BD) is listed as an emerging player. Adamis Pharmaceuticals is listed as an others.
Does Nephron Pharmaceuticals have an API?
No public API is recorded for Nephron Pharmaceuticals.
What industry is Nephron Pharmaceuticals in?
Nephron Pharmaceuticals's product category is Generic Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.